Get the Stockscreener App
2.07
0.98%
0.02
Allogene Therapeutics Inc stock is traded at $2.07, with a volume of 3.17M.
It is up +0.98% in the last 24 hours and up +15.64% over the past month.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
See More
Previous Close:
$2.05
Open:
$2.05
24h Volume:
3.17M
Relative Volume:
0.40
Market Cap:
$715.17M
Revenue:
$22,000
Net Income/Loss:
$-173.76M
P/E Ratio:
-2.695
EPS:
-0.7681
Net Cash Flow:
$-109.53M
1W Performance:
-1.43%
1M Performance:
+15.64%
6M Performance:
-4.17%
1Y Performance:
+88.18%
1-Day Range:
$2.02
$2.10
1-Week Range:
$1.92
$2.19
52-Week Range:
$1.03
$4.46
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
2.07 | 708.26M | 22,000 | -173.76M | -109.53M | -0.7681 |
VRTX
Vertex Pharmaceuticals Inc
|
516.25 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.82 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.77 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.15 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.23 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-26 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-10-26 | Resumed | Jefferies | Buy |
| Jan-09-26 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| May-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
ALLO Reiterated by Citizens -- Price Target Maintained at $6.00 - GuruFocus
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Citizens reiterates Allogene stock rating on trial progress By Investing.com - Investing.com Canada
Citizens reiterates Allogene stock rating on trial progress - Investing.com
Walleye Capital LLC Invests $6.80 Million in Allogene Therapeutics, Inc. $ALLO - MarketBeat
Allogene Therapeutics (ALLO): Frazier funds disclose 5.6% ownership and affiliated stakes - Stock Titan
Allogene Therapeutics (ALLO) Income Statement & Earnings - Moomoo
Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy - CRISPR Medicine News
State Street Corp Expands Allogene Therapeutics (ALLO) Stake wit - GuruFocus
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs - The Globe and Mail
A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $9 to $14 - Moomoo
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says - marketscreener.com
TD Cowen Maintains Allogene Therapeutics(ALLO.US) With Buy Rating - Moomoo
Allogene Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
722,928 Shares in Allogene Therapeutics, Inc. $ALLO Acquired by Hennion & Walsh Asset Management Inc. - marketbeat.com
Allogene Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Allogene Therapeutics Inc (ALLO) (Q2 2026) Earnings Call Highlights: RMAT Designation and Rapid ... - Yahoo Finance
Allogene Therapeutics Inc (ALLO) (Q2 2026) Earnings Call Highlig - GuruFocus
Allogene Therapeutics Inc (ALLO) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Allogene Therapeutics (ALLO) Advances Clinical Pipeline Amidst H - GuruFocus
Allogene Therapeutics: Q2 Earnings Snapshot - AOL.com
Allogene Therapeutics Q2 2026: EPS beats, cash extends to 2029 - scanx.trade
Transcript : Allogene Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
Allogene Therapeutics Announces Q2 2026 Financial Results Highlighting Reduced Losses, First Collaboration Revenue, and Significant Equity Raise - Kalkine Media
Earnings call transcript: Allogene Therapeutics beats Q2 2026 EPS forecast By Investing.com - Investing.com Canada
Allogene Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Allogene Therapeutics Q2 Earnings Call Highlights - marketbeat.com
Earnings call transcript: Allogene Therapeutics beats Q2 2026 EPS forecast - Investing.com
Allogene TherapeuticsMay Offer Up To $500 Million In Securities - TradingView
Allogene Therapeutics Q2 Loss Narrows - marketscreener.com
Allogene Therapeutics (NASDAQ:ALLO) Issues Earnings Results, Beats Estimates By $0.04 EPS - marketbeat.com
Earnings Flash (ALLO) Allogene Therapeutics Posts Q2 Loss $0.13 per Share, vs. FactSet Est of $0.17 Loss - marketscreener.com
Allogene posts $42.7 million Q2 loss as cash reaches $423.6 million - Quiver Quantitative
Allogene Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ALLO: ALPHA3 interim results highlight cema-cel's promise in LBCL and strong financial runway - TradingView
Allogene Therapeutics, Inc. Announces Cemacabtagene Ansegedleucel (Cema-Cel) Is Being Evaluated in Alpha3, the First Pivotal, Randomized Phase 2 Trial in LBCL - marketscreener.com
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update - GlobeNewswire
Allogene Therapeutics Inc (ALLO) Q2 2026 Earnings Report Preview: What To Look For - Yahoo Finance
Allogene Therapeutics (ALLO) Short Interest & Short Float | Updated Aug 2026 $ALLO - marketbeat.com
Allogene Therapeutics, Inc. expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Allogene Therapeutics (ALLO) stake: Belldegrun group reports 3.9% ownership - Stock Titan
State Street Corporation (ALLO) discloses 5.5% beneficial stake in Allogene - Stock Titan
Allogene Therapeutics (ALLO) Institutional Ownership 2026 $ALLO - MarketBeat
Allogene Therapeutics, Inc. (ALLO) Options Chain - Yahoo Finance
Allogene Therapeutics (ALLO) Expected to Release Quarterly Earnings on Wednesday - MarketBeat
William Blair Maintains Allogene Therapeutics(ALLO.US) With Buy Rating - Moomoo
Allogene Therapeutics Q2 Results: Earnings Call Set for Aug 12 - scanx.trade
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update - The Manila Times
Allogene sets Aug. 12 update on cancer and autoimmune disease - Stock Titan
Analysts’ Top Healthcare Picks: Repligen (RGEN), Allogene Therapeutics (ALLO) - The Globe and Mail
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Allogene Therapeutics Inc Stock (ALLO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Yoshiyama Annie | SVP, Finance |
Apr 21 '26 |
Sale |
2.31 |
9,586 |
22,144 |
124,517 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):